Lebrikizumab vs Other Systemic Monotherapies for Moderate-to-Severe Atopic Dermatitis: Network Meta-analysis of Efficacy.

Silverberg JI, Bieber T, Paller AS, Beck L, Kamata M, Puig L, Wiseman M, Ezzedine K, Irvine AD, Foley P, Del Rosso J, Gold LS, Johansson E, Dossenbach M, Gallo G, Akmaz B, Casillas M, Karlsson A, Curteis T, Chovatiya R

Open source

DOI
10.1007/s13555-025-01357-7
Published
2025 Mar
Container
Dermatology and therapy
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1007/s13555-025-01357-7,
  title = {Lebrikizumab vs Other Systemic Monotherapies for Moderate-to-Severe Atopic Dermatitis: Network Meta-analysis of Efficacy.},
  author = {Silverberg JI and Bieber T and Paller AS and Beck L and Kamata M and Puig L and Wiseman M and Ezzedine K and Irvine AD and Foley P and Del Rosso J and Gold LS and Johansson E and Dossenbach M and Gallo G and Akmaz B and Casillas M and Karlsson A and Curteis T and Chovatiya R},
  year = {2025},
  journal = {Dermatology and therapy},
  doi = {10.1007/s13555-025-01357-7},
  url = {https://doi.org/10.1007/s13555-025-01357-7}
}

RIS

TY  - JOUR
TI  - Lebrikizumab vs Other Systemic Monotherapies for Moderate-to-Severe Atopic Dermatitis: Network Meta-analysis of Efficacy.
AU  - Silverberg JI
AU  - Bieber T
AU  - Paller AS
AU  - Beck L
AU  - Kamata M
AU  - Puig L
AU  - Wiseman M
AU  - Ezzedine K
AU  - Irvine AD
AU  - Foley P
AU  - Del Rosso J
AU  - Gold LS
AU  - Johansson E
AU  - Dossenbach M
AU  - Gallo G
AU  - Akmaz B
AU  - Casillas M
AU  - Karlsson A
AU  - Curteis T
AU  - Chovatiya R
PY  - 2025
JO  - Dermatology and therapy
DO  - 10.1007/s13555-025-01357-7
UR  - https://doi.org/10.1007/s13555-025-01357-7
ER  - 

APA

JI, S., T, B., AS, P., L, B., M, K., L, P., M, W., K, E., AD, I., P, F., J, D. R., LS, G., E, J., M, D., G, G., B, A., M, C., A, K., T, C., & R, C. (2025). Lebrikizumab vs Other Systemic Monotherapies for Moderate-to-Severe Atopic Dermatitis: Network Meta-analysis of Efficacy.. Dermatology and therapy. https://doi.org/10.1007/s13555-025-01357-7

Source records